AbCellera Biologics (NASDAQ:ABCL – Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.
AbCellera Biologics (NASDAQ:ABCL – Get Free Report) last released its earnings results on Tuesday, May 7th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. AbCellera Biologics had a negative return on equity of 12.61% and a negative net margin of 410.47%. The company had revenue of $9.95 million during the quarter, compared to analysts’ expectations of $10.73 million. During the same quarter last year, the business posted ($0.14) EPS. The firm’s revenue for the quarter was down 18.4% compared to the same quarter last year. On average, analysts expect AbCellera Biologics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
AbCellera Biologics Trading Down 4.3 %
Shares of ABCL stock opened at $2.92 on Monday. The company’s fifty day moving average price is $3.21 and its 200-day moving average price is $4.09. The stock has a market cap of $858.64 million, a PE ratio of -5.62 and a beta of 0.39. AbCellera Biologics has a 12 month low of $2.65 and a 12 month high of $7.10.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on AbCellera Biologics
AbCellera Biologics Company Profile
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
Read More
- Five stocks we like better than AbCellera Biologics
- What Investors Need to Know About Upcoming IPOs
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- What Are Growth Stocks and Investing in Them
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.